Olaparib in Pakistan (Olaparix 150 mg) – Beacon Pharma

Description

Olaparib in Pakistan (Olaparix 150 mg) – Beacon Pharmaceuticals Ltd.

• Price in Pakistan: PKR 255,000 per pack
• Pack Size: 120 tablets per pack
• Manufacturer: Beacon Pharmaceuticals Ltd.

Olaparib in Pakistan (Olaparix 150 mg)

Olaparix 150 mg (Olaparib) by Beacon Pharmaceuticals Ltd. is an advanced, targeted anticancer medication designed to treat specific types of cancers associated with BRCA gene mutations.

It belongs to a novel class of drugs known as PARP (Poly ADP-Ribose Polymerase) inhibitors, which work by blocking the PARP enzyme involved in DNA repair within cancer cells.

This inhibition prevents cancer cells from repairing themselves, leading to their death—while sparing most normal, healthy cells.

Olaparix is a high-quality formulation developed under strict pharmaceutical standards by Beacon Pharma, a reputed oncology medicine manufacturer known for providing cost-effective alternatives to globally recognized brands such as Lynparza (AstraZeneca).

Therapeutic Uses of Olaparib in Pakistan (Olaparix 150 mg)

Olaparix (Olaparib) is indicated for the treatment of the following conditions:

1. Ovarian Cancer:

   • As maintenance therapy in adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

2. Breast Cancer:

   • For the treatment of adult patients with HER2-negative metastatic breast cancer with confirmed BRCA1 or BRCA2 mutations.

3. Pancreatic Cancer:

   • For maintenance treatment of adult patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.

4. Prostate Cancer:

   • For the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who have BRCA1/2 or other DNA repair gene mutations and who have been previously treated with enzalutamide or abiraterone.

Mechanism of Action of Olaparib in Pakistan (Olaparix 150 mg)

Olaparib inhibits the enzyme PARP, which helps repair damaged DNA in cells. Cancer cells with BRCA mutations rely heavily on PARP for survival.

By blocking PARP, Olaparib induces synthetic lethality, leading to cancer cell death and reduction in tumor growth. This targeted mechanism makes Olaparix effective and relatively selective, reducing harm to normal cells.

Olaparib in Pakistan (Olaparix 150 mg) Dose:

• Recommended Dose: 300 mg twice daily (i.e., two tablets of 150 mg each, morning and evening).

• Route of Administration: Oral

• Duration: Continue until disease progression or unacceptable toxicity.

Note: Dosage should be individualized based on the patient’s clinical condition and physician’s judgment.

Olaparib Side Effects

Common side effects associated with Olaparix include:

• Fatigue or weakness

• Nausea, vomiting

• Anemia, leukopenia

• Headache

• Diarrhea or constipation

• Loss of appetite

• Abdominal discomfort

Serious adverse effects (rare):

• Myelodysplastic syndrome (MDS) / Acute Myeloid Leukemia (AML)

• Pneumonitis

Patients should be monitored regularly with complete blood counts and liver function tests.

Precautions While Using Olaparib:

• Not recommended during pregnancy or breastfeeding.

• Use with caution in patients with hepatic or renal impairment.

• Regular hematological monitoring is advised.

• Avoid concomitant use with strong CYP3A inhibitors or inducers.

Storage:

Store below 30°C in a cool, dry place, away from light and moisture. Keep out of reach of children.

Disclaimer:

This medication should only be used under the supervision of a qualified oncologist or healthcare professional.
The image shown may differ from the actual product.
All information is provided for educational purposes only and should not replace medical advice.

Olaparib Summarized: